Cite
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.
MLA
Liu, Zhihong, et al. “Randomised Clinical Trial: 48 Weeks of Treatment with Tenofovir Amibufenamide versus Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B.” Alimentary Pharmacology & Therapeutics, vol. 54, no. 9, Nov. 2021, pp. 1134–49. EBSCOhost, https://doi.org/10.1111/apt.16611.
APA
Liu, Z., Jin, Q., Zhang, Y., Gong, G., Wu, G., Yao, L., Wen, X., Gao, Z., Huang, Y., Yang, D., Chen, E., Mao, Q., Lin, S., Shang, J., Gong, H., Zhong, L., Yin, H., Wang, F., Hu, P., & Xiao, L. (2021). Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 54(9), 1134–1149. https://doi.org/10.1111/apt.16611
Chicago
Liu, Zhihong, Qinglong Jin, Yuexin Zhang, Guozhong Gong, Guicheng Wu, Lvfeng Yao, Xiaofeng Wen, et al. 2021. “Randomised Clinical Trial: 48 Weeks of Treatment with Tenofovir Amibufenamide versus Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B.” Alimentary Pharmacology & Therapeutics 54 (9): 1134–49. doi:10.1111/apt.16611.